Skip to main content
  • Careers
  • Contact
  • en   it

Navigazione principale

  • About us
  • GMP Solutions
    • Our services
    • Viral Vector
    • Genetically Modified Cells
    • Facilities
  • PIPELINE
    • Our products
    • CAR-T platform
    • CAR-NK
  • Investors
  • Governance
  • News & Events

Navigazione principale

  • About us
  • GMP Solutions
    • Our services
    • Viral Vector
    • Genetically Modified Cells
    • Facilities
  • PIPELINE
    • Our products
    • CAR-T platform
    • CAR-NK
  • Investors
  • Governance
  • News & Events

MolMed is now part of AGC Biologics

Learn more

AGC Biologics

Investors

OPA
OPA ▾

Menu Investors Sidebar

  • Stock information
  • Press releases
  • Notices
  • Presentations
  • Shareholders’ structure
  • Financial reports
  • Analyst coverage
  • IPO
  • OPA
  • Shareholders meetings
  • Events
  • Internal dealing
  • Financial Calendar
Announcement PTO_FINAL171.06 KB Notice pursuant to art. 102253.52 KB Essential information on AGCFininvest Agreement, pursuant to Art. 130 of Issuers' Regulation (in Italian)45.12 KB Abstract of notice (in Italian) of Shareholders' agreement between AGC and Fininvest pursuant Art 129 of Issuers' Regulation15.16 KB Filing of the Offert Document with Consob146.3 KB Suspension of the terms of Consob administrative procedure57.3 KB Timing for the approval of the Offer Document update102.84 KB Update on the timing for the approval of ACG Offer Document55.41 KB Update on the timing for the approval of ACG Offer Document68.53 KB Issuer Statement approval pursuant 103 TUF89.22 KB takeover form - OPA MolMed (In Italian)260.94 KB Issuer Statement pursuant 103 TUF integration131.16 KB Press release - Golden Power Condition.pdf112.38 KB Press release - Waiver to the Golden Power Condition.pdf111.09 KB Press release - Provisional results of the Offer.pdf76.88 KB Press release - Definitive results of the Offer.pdf70.2 KB Press release - Sell-out procedure.pdf135.17 KB Press Release - Provisional results sell-out.pdf78.74 KB Press Release - Final results.pdf125.3 KB Press Release - Delisting.pdf107.44 KB

Subscribe to press releases

By subscribing to this newsletter, you confirm that you have read the Privacy Policy and agree to receive MolMed's press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations. 
In addition, the "work with us" section is still active, while the contact details are no longer accessible.

Leading the way in Cell and Gene therapy

MolMed S.p.A.
Via Olgettina, 58
20132 Milano, Italy
+39 0221277.1
info@molmed.com
Privacy & Cookie Policy

About us

About us ▾

aboutus

  • Business model
  • Our Team
  • Scientific advisory board
  • Hystory
  • Careers

Pipeline

Pipeline ▾

pipeline

  • Our products
  • CAR-T platform
  • CAR-NK

GMP Solutions

GMP Solutions ▾

GMP Solutions footer ENG

  • Our services
  • Viral Vectors
  • Genetically Modified Cells
  • Facilities

Investors

Investors ▾

Investors

  • Stock informations
  • Presentations
  • Notices
  • Events
  • Financial Calendar

Governance

Governance ▾

Governance

  • Corporate governance model
  • Corporate governance rules
  • Business ethics
  • Corporate governance reports

News & Events

News ▾

News

  • News & Events
MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italia | Tel. +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Capitale Sociale € 21.819.020,83 i.v. - REA n.1506630 - N. iscrizione Reg. Imprese di Milano - C. F. e P. IVA 11887610159